Related Experiment Video

Updated: Apr 12, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

The role of anti-angiogenesis in non-small-cell lung cancer: an update

Liza C Villaruz1, Mark A Socinski

  • 1Lung Cancer Program, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 5th Floor Cancer Pavilion, Room 567, Pittsburgh, PA, 15232, USA, villaruzl@upmc.edu.

Current Oncology Reports
|May 8, 2015
PubMed

Insights

Targeted therapies blocking vascular endothelial growth factor (VEGF) show promise in non-small-cell lung cancer (NSCLC). Bevacizumab and ramucirumab improve survival, while VEGFR-2 TKIs offer responses but not significant survival benefits.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Vascular endothelial growth factor (VEGF) pathway is crucial for angiogenesis.
  • Targeted therapies against VEGF and its receptors (VEGFRs) are investigated for non-small-cell lung cancer (NSCLC).

Purpose of the Study:

  • To review the current status of VEGF-targeted therapies in NSCLC treatment.
  • To evaluate the efficacy and survival benefits of different VEGF-targeted agents.

Main Methods:

  • Review of clinical studies on VEGF and VEGFR-targeted therapies in NSCLC.
  • Analysis of data on neutralizing antibodies (bevacizumab, aflibercept, ramucirumab) and tyrosine kinase inhibitors (TKIs).

Main Results:

  • Bevacizumab and ramucirumab demonstrate survival advantages in advanced NSCLC when used in specific treatment settings.
  • VEGFR-2 TKIs show responses and improved progression-free survival in certain NSCLC cases, but without significant survival gains.

Conclusions:

  • VEGF-targeted therapies, particularly bevacizumab and ramucirumab, offer survival benefits in NSCLC.
  • Further research is needed to optimize the use of VEGFR-2 TKIs for improved patient survival in NSCLC.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

56
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K